3-chloro-5-methoxy-1,2-benzisothiazole | 23889-41-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 3-chloro-5-methoxy-1,2-benzisothiazole
• 英文别名: 5-Methoxy-3-chlorbenzoisothiazol；3-Chlor-5-methoxy-<1,2>benzisothiazol；3-chloro-5-methoxy-benzo[d]isothiazole；3-Chloro-5-methoxy-1,2-benzothiazole
• CAS: 23889-41-0
• 化学式: C₈H₆ClNOS
• 分子量: 199.661
• InChiKey: KOUSFIWAYYFDKE-UHFFFAOYSA-N

物化性质

• 熔点：
  73.5-74 °C
• 沸点：
  225.8±22.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-chloro-5-methoxy-1,2-benzisothiazole 生成 (5-methoxy-benzo[d]isothiazol-3-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  Vitali; Mingiardi; Maggiali, Farmaco, Edizione Scientifica, 1973, vol. 28, # 1, p. 8 - 18

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴-5-甲氧基苯甲酸 在 sodium hydroxide 、 五氯化磷 、 氯甲酸三氯甲酯 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 3-chloro-5-methoxy-1,2-benzisothiazole
  参考文献：
  名称：

  Synthesis and biological activity of the putative metabolites of the atypical antipsychotic agent tiospirone

  摘要：

  Putative oxidative metabolites of the lead antipsychotic agent tiospirone (1) were synthesized to assist in the identification of the authentic metabolic products found in human urine samples. Thus far, six authentic metabolites have been correlated to the synthetic species. 4a The putative metabolites were further examined in vitro to assess their central nervous system therapeutic potential. SAR analysis of these derivatives indicates that hydroxyl substitution, particularly in the azaspirodecanedione region of the molecule, diminishes the dopamine D-2 affinity of the species without significantly altering the serotonin type-1A and type-2 interactions. In addition, an increase in alpha-1-adrenergic affinity appears to be linked to the attenuation of effects at the dopamine receptors. The biological profile of the 6-hydroxytiospirone metabolite 42 was exemplary in these respects and the in vivo actions of this compound suggest potent antipsychotic potential with a minimal liability for extrapyramidal side effects (EPS). While compound 42 has been unambiguously characterized as an actual human metabolite of tiospirone, the role of 42 in the observed antipsychotic activity of the parent drug, if any, has not yet been determined.

  DOI：

  10.1021/jm00115a024

文献信息

• [EN] NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE L'INTERACTION YAP/TAZ-TEAD ET LEUR UTILISATION DANS LE TRAITEMENT DU MÉSOTHÉLIOME MALIN
  申请人：INVENTIVA

  公开号：WO2017064277A1

  公开（公告）日：2017-04-20

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.

  该发明涉及公式（I）中的化合物，其中R1、R2、R3、R4、R5和R6如描述中所定义。公式（I）中的化合物是YAP/TAZ-TEAD相互作用的抑制剂。
• Benzo-fused heterocyclic anti-ulcer agents
  申请人：American Home Products Corporation

  公开号：US04490527A1

  公开（公告）日：1984-12-25

  Compounds of the formula: ##STR1## wherein B is a moiety having the formula: ##STR2## R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 4-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro. X is SO.sub.2, SO, S or C.dbd.O; and A is amine selected from the group ##STR3## , wherein R.sup.1 is hydrogen or R.sup.2 CH.sub.2 wherein R.sup.2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweralkyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R.sup.3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R.sup.3 is (1-piperidinyl)methyl, R.sup.1 is hydrogen; n is 1 to 4, and the pharmacologically acceptable salts thereof.

  该化合物的结构式为：##STR1## 其中B是具有结构式的基团：##STR2## R是单卤或双卤、氨基、硝基、氰基、羟基、三氟甲基、巯基、低碳链烷基、低碳链烷氧基、4-7碳原子的环烷基、羧基、烷氧羰基、单或双低碳链烷基取代的氨基、烷酰胺基、低碳链硫基、低碳链磺基、磺酰胺基、取代的磺酰胺基、苯基或取代有卤素、低碳链烷基、低碳链烷氧基、三氟甲基、羟基、氨基、氰基或硝基的苯基。X为SO.sub.2、SO、S或C.dbd.O；A是从以下羰基中选择的胺基：##STR3## 其中R.sup.1是氢或R.sup.2 CH.sub.2，其中R.sup.2是单或双低碳链烷氨基、单或双N-低碳链烷基氨基低碳链烷基、(2-呋喃基)甲基氨基、苄氨基、低环烷基氨基、1-吡咯啉基、1-哌啶基、1-六氢吖啶基、1-八氢吖啉基、3-噻唑啉基、4-吗啉基或4-硫代吗啉基；R.sup.3是氢或(1-哌啶基)甲基，但当R.sup.3为(1-哌啶基)甲基时，R.sup.1为氢；n为1至4，及其药理学上可接受的盐。
• Vitali; Gaetani; Mantovani, Farmaco, Edizione Scientifica, 1969, vol. 24, # 4, p. 440 - 448
  作者：Vitali、Gaetani、Mantovani、Agosti

  DOI：——

  日期：——
• NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA
  申请人：Inventiva

  公开号：EP3362448A1

  公开（公告）日：2018-08-22
• INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Inventiva

  公开号：EP3860990A1

  公开（公告）日：2021-08-11